Raffaella Giavazzi

List of Publications by Year
in descending order

174	9,251	34016	46693
papers	citations	52 h-index	89 g-index

180	180	180	10962
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases. Molecular Cancer Therapeutics, 2022, 21, 555-567.	1.9	11
2	PGC1Î±/Î² Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer. Cancer Research, 2022, 82, 1423-1434.	0.4	14
3	Integrated molecular profiling of patientâ€derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities. International Journal of Cancer, 2022, 151, 240-254.	2.3	7
4	The ER stress response mediator ERO1 triggers cancer metastasis by favoring the angiogenic switch in hypoxic conditions. Oncogene, 2021, 40, 1721-1736.	2.6	31
5	Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity. Matrix Biology, 2021, 103-104, 22-36.	1.5	2
6	VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. Journal of Hematology and Oncology, 2021, 14, 186.	6.9	27
7	Impact of ERCC1, XPF and DNA Polymerase Î² Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts. Cancers, 2020, 12, 2398.	1.7	9
8	Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia. Cancers, 2020, 12, 2312.	1.7	5
9	A methodological approach to correlate tumor heterogeneity with drug distribution profile in mass spectrometry imaging data. GigaScience, 2020, 9, .	3.3	5
10	Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma. Carcinogenesis, 2019, 40, 303-312.	1.3	28
11	A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing. ELife, 2019, 8, .	2.8	38
12	Anti-angiogenesis for cancer: Current status and prospects. Thrombosis Research, 2018, 164, S3-S6.	0.8	18
13	Drug-Homogeneity Index in Mass-Spectrometry Imaging. Analytical Chemistry, 2018, 90, 13257-13264.	3.2	6
14	Soluble stromaâ€related biomarkers of pancreaticÂcancer. EMBO Molecular Medicine, 2018, 10, .	3.3	56
15	Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging. Analytica Chimica Acta, 2018, 1042, 1-10.	2.6	7
16	Tumor progression and metastatic dissemination in ovarian cancer after doseâ€dense or conventional paclitaxel and cisplatin plus bevacizumab. International Journal of Cancer, 2018, 143, 2187-2199.	2.3	8
17	Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts. Oncotarget, 2018, 9, 24707-24717.	0.8	14
18	Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists. Angiogenesis, 2017, 20, 233-241.	3.7	22

#	Article	IF	Citations
19	Modeling Cytostatic and Cytotoxic Responses to New Treatment Regimens for Ovarian Cancer. Cancer Research, 2017, 77, 6759-6769.	0.4	4
20	Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging. Scientific Reports, 2016, 6, 39284.	1.6	68
21	Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia. Oncogene, 2016, 35, 6212-6222.	2.6	35
22	Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics. Chinese Journal of Cancer, 2016, 35, 61.	4.9	32
23	Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response. Molecular Cancer Therapeutics, 2016, 15, 125-135.	1.9	56
24	Orthotopic Model of Ovarian Cancer. Methods in Molecular Biology, 2016, 1464, 139-149.	0.4	7
25	Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMPâ€1 and TIMPâ€2 and tumor thrombospondinâ€1. International Journal of Cancer, 2015, 136, 721-729.	2.3	50
26	Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. Clinical and Experimental Metastasis, 2015, 32, 647-658.	1.7	17
27	Inactivating STAT3: bad for tumor, good for muscle. Cell Cycle, 2015, 14, 939-940.	1.3	7
28	Thrombospondinâ€1 is part of a Slugâ€independent motility and metastatic program in cutaneous melanoma, in association with <scp>VEGFR</scp>â€1 and <scp>FGF</scp>â€2. Pigment Cell and Melanoma Research, 2015, 28, 73-81.	1.5	45
29	Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. Oncotarget, 2015, 6, 3043-3054.	0.8	38
30	Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2. Oncotarget, 2015, 6, 28389-28400.	0.8	13
31	Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations. Cancer Research, 2014, 74, 6980-6990.	0.4	110
32	Vascular Endothelial Growth Factor C Promotes Ovarian Carcinoma Progression through Paracrine and Autocrine Mechanisms. American Journal of Pathology, 2014, 184, 1050-1061.	1.9	56
33	Syngeneic Murine Metastasis Models: B16 Melanoma. Methods in Molecular Biology, 2014, 1070, 131-140.	0.4	29
34	Chemotherapy Counteracts Metastatic Dissemination Induced by Antiangiogenic Treatment in Mice. Molecular Cancer Therapeutics, 2013, 12, 2237-2247.	1.9	23
35	The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts. Molecular Cancer Therapeutics, 2013, 12, 131-140.	1.9	39
36	Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer Chemotherapy and Pharmacology, 2013, 72, 879-887.	1.1	37

#	Article	IF	Citations
37	Tumor Delivery of Chemotherapy Combined with Inhibitors of Angiogenesis and Vascular Targeting Agents. Frontiers in Oncology, 2013, 3, 259.	1.3	65
38	Determination of Paclitaxel Distribution in Solid Tumors by Nano-Particle Assisted Laser Desorption Ionization Mass Spectrometry Imaging. PLoS ONE, 2013, 8, e72532.	1.1	54
39	Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectinâ€“Positive Metastatic Human Melanoma Xenografts. Cancer Research, 2012, 72, 1814-1824.	0.4	86
40	Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. British Journal of Cancer, 2012, 107, 360-369.	2.9	29
41	A complex of Î±₆ integrin and Eâ€cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietinâ€like 6. EMBO Molecular Medicine, 2012, 4, 1156-1175.	3.3	44
42	Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies. Neoplasia, 2012, 14, 846-IN16.	2.3	28
43	Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumorâ€™s proangiogenic microenvironment. Cellular and Molecular Life Sciences, 2012, 69, 1167-1178.	2.4	40
44	Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery. Histochemistry and Cell Biology, 2012, 137, 195-204.	0.8	14
45	Targeting angiogenesis with compounds from the extracellular matrix. International Journal of Biochemistry and Cell Biology, 2011, 43, 1674-1685.	1.2	36
46	Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks. Thrombosis and Haemostasis, 2011, 106, 705-711.	1.8	18
47	Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression. British Journal of Dermatology, 2011, 164, 1061-1070.	1.4	25
48	The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO Molecular Medicine, 2011, 3, 480-494.	3.3	67
49	E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models. Cancer Research, 2011, 71, 1396-1405.	0.4	131
50	Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies. Current Pharmaceutical Design, 2010, 16, 3921-3931.	0.9	13
51	A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. Histochemistry and Cell Biology, 2010, 133, 467-475.	0.8	30
52	Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. Clinical and Experimental Metastasis, 2010, 27, 43-53.	1.7	18
53	Non-peptidic Thrombospondin-1 Mimics as Fibroblast Growth Factor-2 Inhibitors. Journal of Biological Chemistry, 2010, 285, 8733-8742.	1.6	70
54	A Proteomic Approach for the Identification of Vascular Markers of Liver Metastasis. Cancer Research, 2010, 70, 309-318.	0.4	40

#	Article	IF	Citations
55	Dual Targeting of Tumor and Endothelial Cells by Gonadotropin-Releasing Hormone Agonists to Reduce Melanoma Angiogenesis. Endocrinology, 2010, 151, 4643-4653.	1.4	15
56	The Immunocytokine F8-IL2 Improves the Therapeutic Performance of Sunitinib in a Mouse Model of Renal Cell Carcinoma. Journal of Urology, 2010, 184, 2540-2548.	0.2	58
57	Interleukin-1Î² regulates the migratory potential of MDAMB231 breast cancer cells through the hypoxia-inducible factor-1Î±. European Journal of Cancer, 2010, 46, 3400-3408.	1.3	44
58	Combination Therapy with Chemotherapy and VDAs. , 2010, , 77-93.		2
59	Comparative Analysis of the Membrane Proteome of Closely Related Metastatic and Nonmetastatic Tumor Cells. Cancer Research, 2009, 69, 5406-5414.	0.4	48
60	Impact of VEGFâ€dependent tumour microâ€environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice. Journal of Pathology, 2009, 219, 455-462.	2.1	17
61	Vascular Disrupting Activity of Tubulin-Binding 1,5-Diaryl-1H-imidazoles. Journal of Medicinal Chemistry, 2009, 52, 7906-7910.	2.9	65
62	Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells. European Journal of Cancer, 2009, 45, 454-460.	1.3	19
63	The Effects of Vandetanib on Paclitaxel Tumor Distribution and Antitumor Activity in a Xenograft Model of Human Ovarian Carcinoma. Neoplasia, 2009, 11, 1155-IN7.	2.3	31
64	In Vivo Measurement of Vascular Modulation in Experimental Tumors Using a Fluorescent Contrast Agent. Photochemistry and Photobiology, 2008, 84, 1249-1256.	1.3	10
65	Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics, 2008, 9, 201.	1.2	56
66	Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. International Journal of Biochemistry and Cell Biology, 2008, 40, 700-709.	1.2	67
67	Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion. Molecular Cancer Research, 2008, 6, 525-534.	1.5	65
68	Microtubule Targeting Agents and the Tumor Vasculature. , 2008, , 519-530.		4
69	Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. British Journal of Cancer, 2007, 97, 888-894.	2.9	49
70	Vascular endothelium summary statement III: Cancer prevention and control. Vascular Pharmacology, 2007, 46, 321-323.	1.0	2
71	Tumorâ€™host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. Cancer and Metastasis Reviews, 2007, 26, 481-488.	2.7	12
72	Bioavailability of VEGF in Tumor-Shed Vesicles Depends on Vesicle Burst Induced by Acidic pH. Neoplasia, 2006, 8, 96-103.	2.3	168

#	Article	IF	Citations
73	Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. European Journal of Cancer, 2006, 42, 2821-2832.	1.3	90
74	Stereochemically pure Î±-trifluoromethyl-malic hydroxamates: synthesis and evaluation as inhibitors of matrix metalloproteinases. Tetrahedron, 2006, 62, 10171-10181.	1.0	7
75	The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. Clinical Cancer Research, 2006, 12, 1839-1849.	3.2	54
76	Fluorescent imaging of vascular shutdown in-vivo. , 2006, , .		0
77	Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukaemias in vitro and in vivo. British Journal of Haematology, 2005, 128, 310-317.	1.2	52
78	In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nature Methods, 2005, 2, 291-298.	9.0	141
79	Solution state conformation and degradation of cyclopeptides containing an NGR motif. Journal of Peptide Science, 2005, 11, 53-59.	0.8	6
80	Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Molecular Cancer Therapeutics, 2005, 4, 715-725.	1.9	27
81	Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies. Clinical Cancer Research, 2005, 11, 2720-2726.	3.2	23
82	Glycerophosphoinositols inhibit the ability of tumour cells to invade the extracellular matrix. European Journal of Cancer, 2005, 41, 470-476.	1.3	21
83	Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thrombosis and Haemostasis, 2004, 91, 403-411.	1.8	28
84	Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin. Clinical Cancer Research, 2004, 10, 4813-4821.	3.2	144
85	Antiangiogenic activity of aplidine, a new agent of marine origin. British Journal of Cancer, 2004, 90, 2418-2424.	2.9	82
86	An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene, 2004, 23, 8859-8867.	2.6	61
87	Synthesis and evaluation of stereopure Î±-trifluoromethyl-malic hydroxamates as inhibitors of matrix metalloproteinases. Tetrahedron Letters, 2004, 45, 1611-1615.	0.7	47
88	Invasion and Metastasis. , 2004, , 443-461.		4
89	Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. Molecular Cancer Therapeutics, 2004, 3, 111-21.	1.9	46
90	Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia, 2003, 17, 52-59.	3.3	142

#	Article	IF	Citations
91	Distinct Role of Fibroblast Growth Factor-2 and Vascular Endothelial Growth Factor on Tumor Growth and Angiogenesis. American Journal of Pathology, 2003, 162, 1913-1926.	1.9	167
92	IDN 5390: a new concept in taxane development. Anti-Cancer Drugs, 2003, 14, 255-258.	0.7	9
93	Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood, 2003, 102, 4399-4406.	0.6	93
94	Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Research, 2003, 63, 1534-7.	0.4	94
95	The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clinical Cancer Research, 2003, 9, 3476-85.	3.2	45
96	Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Research, 2003, 63, 5224-9.	0.4	241
97	Shedding of the Matrix Metalloproteinases MMP-2, MMP-9, and MT1-MMP as Membrane Vesicle-Associated Components by Endothelial Cells. American Journal of Pathology, 2002, 160, 673-680.	1.9	502
98	Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clinical Cancer Research, 2002, 8, 1182-8.	3.2	50
99	Small molecules in anti-angiogenic therapy. Current Opinion in Investigational Drugs, 2002, 3, 482-91.	2.3	1
100	Syngeneic Murine Metastasis Models: B16 Melanoma. , 2001, 58, 223-229.		5
101	Anticancer Therapy with Angiogenesis Inhibitors. Tumori, 2001, 87, 14-16.	0.6	1
102	Preclinical development of metalloproteasis inhibitors in cancer therapy. Critical Reviews in Oncology/Hematology, 2001, 37, 53-60.	2.0	41
103	p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene, 2001, 20, 7293-7300.	2.6	51
104	Inhibition of matrix metalloproteinases by overâ€expression of tissue inhibitor of metalloproteinaseâ€2 inhibits the growth of experimental hemangiomas. International Journal of Cancer, 2001, 91, 241-247.	2.3	29
105	Thrombospondinâ€1/HIVâ€1 Tat protein interaction: modulation of the biological activity of extracellular Tat. FASEB Journal, 2000, 14, 1917-1930.	0.2	27
106	The heparin binding 25 kDa fragment of thrombospondinâ€1 promotes angiogenesis and modulates gelatinase and TIMPâ€2 production in endothelial cells. FASEB Journal, 2000, 14, 1674-1676.	0.2	146
107	Posttranscriptional Stimulation of Endothelial Cell Matrix Metalloproteinases 2 and 1 by Endothelioma Cells. Experimental Cell Research, 2000, 258, 384-394.	1.2	43
108	Endothelin-1 Induces an Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. American Journal of Pathology, 2000, 157, 1703-1711.	1.9	322

#	Article	IF	Citations
109	Driving p53 Response to Bax Activation Greatly Enhances Sensitivity to Taxol by Inducing Massive Apoptosis. Neoplasia, 2000, 2, 202-207.	2.3	22
110	CHARACTERIZATION OF NOVEL CLONAL MURINE ENDOTHELIAL CELL LINES WITH AN EXTENDED LIFE SPAN. In Vitro Cellular and Developmental Biology - Animal, 2000, 36, 299.	0.7	7
111	Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. Blood, 2000, 95, 2672-2682.	0.6	5
112	Eso Conference â€œBiological Basis for Antiangiogenic Therapyâ€• International Journal of Biological Markers, 1999, 14, 277-277.	0.7	0
113	Adhesion of Tumor Cells Under Flow. , 1999, 96, 153-157.		2
114	Adhesion of Tumor Cells to Endothelium Under Static Conditions. , 1999, 96, 147-151.		0
115	The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cells. Annals of Oncology, 1999, 10, 589-591.	0.6	15
116	Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells. Clinical and Experimental Metastasis, 1999, 17, 655-662.	1.7	35
117	Mesothelial cells induce the motility of human ovarian carcinoma cells. , 1999, 80, 303-307.		44
118	Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. , 1999, 188, 76-81.		44
119	High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Annals of Oncology, 1999, 10, 1233-1240.	0.6	90
120	Human Immunodeficiency Virus-1 (HIV-1)-Tat Protein Promotes Migration of Acquired Immunodeficiency Syndromeâ€“Related Lymphoma Cells and Enhances Their Adhesion to Endothelial Cells. Blood, 1999, 94, 1747-1754.	0.6	5
121	Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional morphometric study. American Journal of Pathology, 1998, 152, 1607-16.	1.9	36
122	Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clinical Cancer Research, 1998, 4, 1977-83.	3.2	88
123	Outbreaks of hyperkeratotic dermatitis of athymic nude mice in northern Italy. Laboratory Animals, 1997, 31, 206-211.	0.5	28
124	A human acute lymphoblastic leukemia line with the T(4;11) translocation as a model of minimal residual disease in SCID mice. Leukemia Research, 1997, 21, 1107-1114.	0.4	18
125	Effect of alltrans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells. , 1997, 70, 72-77.		21
126	IL-1Î± gene-transfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice. , 1996, 67, 856-863.		34

#	Article	IF	Citations
127	Matrix metalloproteinase inhibition: A review of anti-tumour activity. Annals of Oncology, 1995, 6, 967-974.	0.6	203
128	Establishment of human acute myelogenous leukemia lines secreting interleukin-1Î² in SCID mice. International Journal of Cancer, 1995, 61, 280-285.	2.3	14
129	Transfer of the HSV-tk Gene into Donor Peripheral Blood Lymphocytes for In Vivo Modulation of Donor Anti-Tumor Immunity after Allogeneic Bone Marrow Transplantation. The San Raffaele Hospital, Milan, Italy. Human Gene Therapy, 1995, 6, 813-819.	1.4	137
130	Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action. Cancer Research, 1995, 55, 4729-38.	0.4	30
131	Cytokines and Cell Adhesion Molecules in Tumor-Endothelial Cell Interaction and Metastasis. Cell Adhesion and Communication, 1994, 2, 219-224.	1.7	15
132	Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. International Journal of Cancer, 1994, 58, 460-464.	2.3	212
133	Enhancement of Metastatic Potential of Murine and Human Melanoma Cells by Laminin Receptor Peptide G: Attachment of Cancer Cells to Subendothelial Matrix as a Pathway for Hematogenous Metastasis. Journal of the National Cancer Institute, 1993, 85, 235-240.	3.0	44
134	Retroviral Vector-Mediated Gene Transfer into Human Primary Myogenic Cells Leads to Expression in Muscle FibersIn Vivo. Human Gene Therapy, 1993, 4, 713-723.	1.4	61
135	Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. Annals of Oncology, 1993, 4, 151-155.	0.6	24
136	A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.. Journal of Clinical Investigation, 1993, 92, 2160-2167.	3.9	107
137	Rolling and adhesion of human tumor cells on vascular endothelium under physiological flow conditions.. Journal of Clinical Investigation, 1993, 92, 3038-3044.	3.9	197
138	Comparative study on the metastatic behavior of human tumors in nude, beige/nude/xid and severe combined immunodeficient mice. Invasion & Metastasis, 1993, 13, 82-91.	0.5	38
139	Interleukin 1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin 1 or lipopolysaccharide in a human melanoma/nude mouse system. Cancer Research, 1993, 53, 5051-4.	0.4	58
140	Matrigel promotes retinoblastoma cell growthin vitro andin vivo. International Journal of Cancer, 1992, 52, 234-240.	2.3	46
141	Thrombospondin modulates basic fibroblast growth factor activities on endothelial cells. Exs, 1992, 61, 210-213.	1.4	15
142	Soluble intercellular adhesion molecule 1 is released by human melanoma cells and is associated with tumor growth in nude mice. Cancer Research, 1992, 52, 2628-30.	0.4	81
143	An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science, 1991, 251, 1363-1366.	6.0	132
144	Organ-specific growth of a murine lymphoma of spontaneous origin in nude mice. Clinical and Experimental Metastasis, 1991, 9, 485-497.	1.7	2

#	Article	IF	Citations
145	Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor.. Journal of Cell Biology, 1990, 111, 765-772.	2.3	392
146	Retention of vital dyes correlates inversely with the multidrug-resistant phenotype of adriamycin-selected murine fibrosarcoma variants. Experimental Cell Research, 1990, 190, 69-75.	1.2	36
147	Tumorigenic and Metastatic Properties of Human Colorectal Carcinomas Transplanted into Nude Mouse. , 1990, , 311-339.		1
148	Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Research, 1990, 50, 4771-5.	0.4	159
149	Flavone acetic acid pharmacokinetics in nude mice. Anticancer Research, 1990, 10, 437-9.	0.5	3
150	Organ distribution of experimental metastases of a human colorectal carcinoma injected in nude mice. Clinical and Experimental Metastasis, 1989, 7, 55-68.	1.7	42
151	Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. International Journal of Cancer, 1989, 44, 494-500.	2.3	58
152	Membrane fluidity affects tumor-cell motility, invasion and lung-colonizing potential. International Journal of Cancer, 1989, 44, 707-713.	2.3	99
153	Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts. British Journal of Cancer, 1988, 57, 277-280.	2.9	33
154	Interleukin 1 promotes tumor cell adhesion to cultured human endothelial cells.. Journal of Clinical Investigation, 1988, 82, 1466-1470.	3.9	132
155	The Nude Mouse for the Study of Human Colorectal Carcinoma. Advances in Experimental Medicine and Biology, 1988, 233, 39-47.	0.8	1
156	Distribution of mono-, di, and tri-O-acetylated sialic acids in normal and neoplastic colon. Cancer Research, 1988, 48, 483-9.	0.4	41
157	Growth potential of human colorectal carcinomas in nude mice: association with the preoperative serum concentration of carcinoembryonic antigen in patients. Cancer Research, 1988, 48, 1689-92.	0.4	58
158	Differential expression of a sialoglycoprotein with an approximate molecular weight of 900,000 on metastatic human colon carcinoma cells growing in culture and in tumor tissues. Cancer Research, 1988, 48, 2353-60.	0.4	31
159	Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 975), a new anticancer agent. European Journal of Cancer & Clinical Oncology, 1987, 23, 1529-1535.	0.9	39
160	Growth and metastatic behavior of human tumor cells implanted into nude and beige nude mice. Clinical and Experimental Metastasis, 1987, 5, 135-146.	1.7	27
161	Correlation between the in vitro interaction of tumor cells with an organ environment and metastatic behavior in vivo. Invasion & Metastasis, 1987, 7, 16-29.	0.5	39
162	Tumor-derived suppressor factors (TDSFs) in normal and neoplastic colon and rectum. Journal of Surgical Research, 1986, 40, 467-474.	0.8	9

#	Article	IF	Citations
163	Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Research, 1986, 46, 4109-15.	0.4	390
164	Expression of cell surface P-glycoprotein by an Adriamycin-resistant murine fibrosarcoma. Cancer Chemotherapy and Pharmacology, 1984, 13, 145-7.	1.1	28
165	Correlation of Tumor Growth Inhibitory Activity of Macrophages Exposed to Adriamycin and Adriamycin Sensitivity of the Target Tumor Cells234. Journal of the National Cancer Institute, 1984, 73, 447-455.	3.0	34
166	Mononuclear phagocyte adherence in the presence of laminin. Experimental Cell Research, 1983, 146, 391-399.	1.2	25
167	Isolation and preliminary characterization of an Adriamycin-resistant murine fibrosarcoma cell line. Cancer Research, 1983, 43, 2216-22.	0.4	32
168	Laminin inhibits the adhesion of a murine tumor of macrophage origin. Experimental Cell Research, 1982, 140, 315-322.	1.2	17
169	Tumour sublines with different metastatic capacity induce similar blood coagulation changes in the host. British Journal of Cancer, 1981, 43, 100-104.	2.9	13
170	Characterization of tumor lines derived from spontaneous metastases of a transplanted murine sarcoma. European Journal of Cancer, 1981, 17, 71-76.	1.0	55
171	A murine ovarian tumor with unique metastasizing capacity. European Journal of Cancer, 1981, 17, 651-653.	1.0	19
172	Procoagulant activity of sarcoma sublines with different metastatic potential. Blood, 1981, 57, 733-735.	0.6	6
173	Divergent effects of macrophage toxins on growth of primary tumors and lung metastases in mice. International Journal of Cancer, 1980, 25, 617-620.	2.3	60
174	Metastasizing capacity of tumour cells from spontaneous metastases of transplanted murine tumours. British Journal of Cancer, 1980, 42, 462-472.	2.9	102